Skip to main content
Journal of Crohn's & Colitis logoLink to Journal of Crohn's & Colitis
. 2022 Aug 16;17(1):149. doi: 10.1093/ecco-jcc/jjac104

Correction

PMCID: PMC10060704  PMID: 35971821

On 2-Jan-2024 this Correction Notice was amended to confirm the following:

Until 2016, the De Simone Formulation (DSF) was sold as VSL#3® and had established its efficacy in inflammatory bowel diseases. After 2016, the VSL#3® product no longer contains DSF. Accordingly, the VSL#3 references in the ECCO Guidelines 2017 exclusively endorse DSF supported by scientific evidence.

The earlier version of this Correction Notice is retained below per decision of the Commercial Court of Vienna of 28 September 2023:

This article contains studies and/or references to a probiotic known as VSL#3. The formulation of the currently available VSL #3 is not the same as the VSL#3 that has been scientifically assessed in studies that are subject of this article or are referenced to in this article.

This correction notice applies to the following papers:


Articles from Journal of Crohn's & Colitis are provided here courtesy of Oxford University Press

RESOURCES